Objectives
-
Multiple objectives
To meet the scientific challenges posed by health data, Heva mobilizes expertise, the most relevant data sources (ad hoc data collection, secondary data, linked data, etc.), study designs (cross-sectional studies, cohorts, case-controls, etc.) and analysis methodologies (adjustment, propensity score, clustering, etc.) to best suit to your research questions.
This enables Heva to cover a wide range of fields of investigation, from the identification and description of target populations, to studies of utilization, efficacy and comparative safety, HEOR, etc.
Epidemiology
Efficiency and safety
Care pathways
Proper use and adherence to recommendations
Medical economics
Care offering
Epidemiology
We characterize target populations, epidemiological indicators (incidence, prevalence, mortality, etc.), care practices and large-scale therapeutic trajectories. These analyses are essential to document the epidemiology of a pathology, supporting a marketing authorization application or preparing an HAS evaluation.
See our references
Attarian, S., Camdessanché, J.-P., Echaniz-Laguna, A., Ciumas, M., Blein, C., Grenier, B., & Solé, G. (2024). Tracking myasthenia gravis severity over time: Insights from the French health insurance claims database. European Journal of Neurology. Advance online publication.
Touzeau, C., Raguideau, F., Denis, H., Lamarsalle, L., Guilmet, C., Javelot, M., Pierres, M., & Perrot, A. (2025, May 8). Epidemiology of patients treated for multiple myeloma using a new algorithm in the French national health insurance database (SNDS): Results from the MYLORD study. Journal Name. Advance online publication.
Efficiency and safety
In a clinical trial, we evaluate toxicity and the minimum effective dose in healthy or sick volunteers. The drug may be granted marketing authorization (AMM) by the ANSM if its therapeutic value is proven, and if it is safe for the patient and can be used in complete safety. Medical devices, on the other hand, will obtain CE marking once their clinical performance and safety have been demonstrated through exploratory and confirmatory clinical investigations.
We also use robust methodologies (propensity scores, longitudinal analyses, causal models) to compare the performance of different therapeutic options in real life. These results strengthen comparative evaluation dossiers and scientific publications. Heva designs and carries out real-life studies in line with the requirements of health authorities (EMA, ANSM), in particular PASS and post-marketing follow-up studies. Our protocols are validated by regulatory authorities and conducted in accordance with good epidemiological practice (ENCePP, ISPE, STROBE, RECORD-PE).
See our references
Bricout, H., Levant, M.-C., Assi, N., Crépey, P., Descamps, A., & Mari, K. (2024, December). The relative effectiveness of a high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccines in older adults in France: A retrospective cohort study during the 2021-2022 influenza season. Vaccine, 30(12), 1592-1598.
Grynberg, M., Cedrin-Durnerin, I., Raguideau, F., Herquelot, E., Luciani, L., Porte, F., Verpillat, P., Helwig, C., Schwarze, J. E., Paillet, S., Castello-Bridoux, C., D'Hooghe, T., & Benchaïb, M. (2023, June). Comparative effectiveness of gonadotropins used for ovarian stimulation during assisted reproductive technologies (ART) in France: A real-world observational study from the French nationwide claims database (SNDS). Best Practice & Research Clinical Obstetrics & Gynaecology, 88, 102308.
Gottenberg, J.-E., Mammar, N., Kessouri, M., Rudant, J., Raguideau, F., Grenier, B., & Kirchgesner, J. (2022, December 11-13). Risk of major adverse cardiovascular events and malignancies in rheumatoid arthritis patients treated with tofacitinib or a TNF inhibitor, a national cohort study: the RELATION study [Presentation No. O.071, Hybrid Congress of the French Society of Rheumatology]. Hôpital Hautepierre, Strasbourg, France.
Care pathways
We reconstruct patient care trajectories to identify breakpoints, diagnostic delays and optimization levers. We use dedicated algorithms (TAK, ATLAS, process mining, etc.) to identify and visualize these pathways. These analysis feed the strategic reflections product positioning and institutional discussions.
See our references
Pépin, J. L., Herquelot, E., Denis, H., Josseran, A., Lavergne, F., Benjafield, A., Malhotra, A., Raphelson, J., Cistulli, P., Schmidt, A., Bailly, S., Palot, A., & Prigent, A. (n.d.). Impact of long-term non-invasive ventilation on severe exacerbations and survival in COPD: A French nationwide cohort study using multistate models. Chronic Obstructive Pulmonary Disease
Delaye, M., Grenier, B., Lièvre, A., & Neuzillet, C. (2025, June). Intrahepatic cholangiocarcinoma trends and treatment lines: Real-world evidence from the French National Hospital Discharge database. ESMO Gastrointestinal Oncology, 8, 100152
Proper use and adherence to recommendations
We analyze initiation, persistence and adherence to recommendations, as well as patterns of use of drugs or medical devices. These studies are essential for health product risk management plans (RMPs), regulatory submissions and product differentiation strategies.
See our references
Fernandes, J., Neuzillet, C., Ano, S., Benoist, A., Boileau, C., Coquerelle, S., Ducroux, A., Fraissignes, S., Goyard, N., Grenier, B., Kolahi, C., Lebreton, C., Merle, P., & Chouaid, C. (n.d.). Real-life conditions for durvalumab use in France: a retrospective observational study of patients treated for digestive and/or bronchopulmonary cancer between 2019 and 2023. HEVA.
Panes, A., Cals-Maurette, M., Laurent, M., Bastide, S., Oller, G., Désaméricq, G., Cluzeau, T., & Boissel, N. (n.d.). Adherence indicator adapted to treatment cycles with therapeutic pauses: Example of use in the real-life blinatumomab study in France. HEVA.
Medical economics
We carry out economic and medico-economic studies, as well as estimates of the burden of disease, to provide answers to all these questions. This feed dossiers for the authorities, such as responding to requests for real-life monitoring, or providing insight to healthcare establishments on the impact of the arrival of a new treatment on their organization and financial equilibrium.
See our references
Foux, L., Szwarcensztein, K., Panes, A., Schmidt, A., Herquelot, É., Galvain, T., & Phan Thanh, T. N. (2025). Clinical and economic burden of surgical site infections following selected surgeries in France. PLoS One, 20(6), e0324509.
Lefèvre, G., Borget, I., Lefèvre, C., Maherzi, C., Nucit, A., Hennaoui, M., Schmidt, A., Lennon, H., Grenier, B., Daydé, F., & Mahlaoui, N. (2025, January 24). Healthcare resource utilization and costs in immunodeficient patients receiving subcutaneous Ig: Real-world evidence from France. PLoS One.
Care offering
We also analyze local healthcare provision (density of healthcare professionals, geographical accessibility, use of facilities) to identify regional disparities and areas of greatest need. These data are invaluable in guiding deployment strategies, awareness-raising initiatives and local partnerships.
See our references
Toffart, A.-C., Casanova, G., Pierre, M., Lemasson, H., Moreau-Mallet, V., Pagès, N., Jolivel, R., Panes, A., Chartier, M., & Pérol, M. (2022). Analysis of the healthcare offer and development opportunities for immunotherapy administrations in Hospitalisation À Domicile (HAD) in France in 2022. NRC 14th.
Toffart, A.-C., Casanova, G., Pierre, M., Lemasson, H., Moreau-Mallet, V., Pagès, N., Jolivel, R., Panes, A., Chartier, M., & Pérol, M. (2022). Analysis of the healthcare offer and development opportunities for immunotherapy administrations in Hospitalisation À Domicile (HAD) in France in 2022. NRC 14th.